{"id":429605,"date":"2021-02-04T17:27:08","date_gmt":"2021-02-04T22:27:08","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=429605"},"modified":"2021-02-04T17:27:08","modified_gmt":"2021-02-04T22:27:08","slug":"ortho-clinical-diagnostics-announces-closing-of-full-over-allotment-option-from-initial-public-offering","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ortho-clinical-diagnostics-announces-closing-of-full-over-allotment-option-from-initial-public-offering\/","title":{"rendered":"Ortho Clinical Diagnostics Announces Closing of Full Over-Allotment Option from Initial Public Offering"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n RARITAN, N.J.<\/span>, Feb. 4, 2021<\/span> \/PRNewswire\/ —\u00a0Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) (“Ortho”), the world’s largest pure-play in vitro diagnostics company dedicated to improving and saving lives through innovative laboratory testing and blood-typing solutions, today announced the closing of its sale of an additional 11.4 million ordinary shares pursuant to the over-allotment option granted to the underwriters in Ortho’s initial public offering. The additional shares were sold at $17.00<\/span> per share less underwriting discounts and commissions, generating total additional gross proceeds of approximately $193<\/span>.8\u00a0million. <\/p>\n

\n

\n
\n \"logo\"
\n <\/a>\n <\/p>\n<\/p><\/div>\n

Ortho intends to use the net proceeds from the offering, including the exercise of the over-allotment option, to redeem $160 million<\/span> in aggregate principal amount of 7.375% senior notes due 2025 and $270 million<\/span> in aggregate principal amount of 7.250% senior notes due 2028, in each case issued by certain of Ortho’s subsidiaries, repay borrowings under its dollar term loan facility, and for working capital and general corporate purposes, which may include further repayment of indebtedness.<\/p>\n

The offering was made through an underwriting group led by J.P. Morgan, BofA Securities, and Goldman Sachs & Co. LLC, who acted as lead bookrunning managers, Barclays, Morgan Stanley, Citigroup, Credit Suisse, UBS Investment Bank, Evercore ISI and Piper Sandler<\/span>, who acted as joint bookrunning managers, and ING, Macquarie Capital, Nomura, TCG Capital Markets L.L.C., Drexel Hamilton<\/span>, H.C. Wainwright & Co., Ramirez & Co., Inc. and Siebert Williams Shank<\/span>, who acted as co-managers. <\/p>\n

A registration statement on Form S-1 relating to these securities was declared effective by the Securities and Exchange Commission. This news release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. <\/p>\n

The offering of these securities was made only by means of a prospectus. Copies of the preliminary prospectus may be obtained by contacting: <\/p>\n